IDDA Stock Chart & Stats
€1.73
-€0.05(-3.31%)
At close: 4:00 PM EDT
€1.73
-€0.05(-3.31%)
Day’s Range― - ―
52-Week Range€0.93 - €2.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€140.07M
Enterprise Value€183.29M
Total Cash (Recent Filing)€10.89M
Total Debt (Recent Filing)€20.20M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 25, 2027EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding111,718,925
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.95Price Target Upside243.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€49.14M
Bulls Say, Bears Say
Bulls Say
Lacutamab Partnership And FundingThe Sobi partnership validates lacutamab commercially while providing substantial non-dilutive funding potential through upfront and milestone payments. Its royalty structure can create longer-term economics if development succeeds, and the relationship transfers some commercialization burden to an experienced partner.
Regulatory And Clinical MomentumMultiple regulatory designations can support development efficiency and strengthen lacutamab’s path toward potential approval in a rare cancer setting. They also signal that regulators recognize an important unmet need, which may improve engagement and commercial positioning over the next several quarters.
Broad Oncology PipelineInnate has several avenues for value creation rather than relying on one clinical asset. A completed Phase 3 enrollment, an advancing ADC program, and additional internal ADC approaches provide portfolio diversification and preserve upside from multiple development outcomes.
Bears Say
Negative Shareholders’ EquityNegative equity indicates that cumulative losses have materially eroded the capital base and reduced financial flexibility. Even with lower debt, this condition can increase dependence on future financing, create dilution or refinancing pressure, and constrain the company’s ability to absorb setbacks.
Persistent Cash BurnOngoing cash outflows show that Innate is not currently self-funding its research and development activities. Continued dependence on partner payments, equity financing, or other external capital could limit strategic flexibility and make future clinical expansion sensitive to funding availability.
Revenue Volatility And Operating LossesThe sharp revenue contraction highlights the uneven economics of a development-stage licensing model that lacks broad recurring product sales. Large losses alongside the lower revenue base indicate weak operating leverage and leave earnings dependent on uncertain milestones or successful program advancement.
Innate Pharma News
IDDA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was €0.93 and its highest was €2.18 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is €140.07M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Mar 25, 2027 which is in 161 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Sep 17, 2026. The company reported -€0.212 earnings per share for the quarter, missing the consensus estimate of -€0.163 by -€0.049.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.25.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 111,718,925 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -€0.212 in its last earnings report, missing expectations of -€0.163. Following the earnings report the stock price went up 7.742%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in DE:IDDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.95 (243.88% Upside)
€5.95 (243.88% Upside)
Blogger Sentiment
Bullish
DE:IDDA Sentiment 67%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.55%
12-Months-Change
Fundamentals
Return on Equity
152.56%
Trailing 12-Months
Asset Growth
-63.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Innate Pharma
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
IDDA Company Deck
IDDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook, with the lacutamab partnership closing, Phase 3 initiation, preliminary IPH4.5 thousand objective responses and favorable safety observations, completed monalizumab enrollment, multiple upcoming catalysts, and a cash runway expected through the end of the first quarter of 2028. The main qualifications were that IPH4.5 thousand data remain early, the post-enfortumab vedotin urothelial cancer setting lacks an established second-line standard, and broader development could require additional funding.View all DE:IDDA earnings summariesIDDA Stock 12 Month Forecast
Average Price Target
€5.95
▲(243.88% Upside)